{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T04:42:06Z","timestamp":1790484126748,"version":"4.1.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"2","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1007\/s40121-017-0148-z","type":"journal-article","created":{"date-parts":[[2017,3,6]],"date-time":"2017-03-06T09:28:50Z","timestamp":1488792530000},"page":"225-231","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["The Safety and Economic Impact of Cefazolin versus Nafcillin for the Treatment of Methicillin-Susceptible Staphylococcus aureus Bloodstream Infections"],"prefix":"10.1007","volume":"6","author":[{"given":"Lauren K.","family":"Flynt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel M.","family":"Kenney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus J.","family":"Zervos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan L.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,3,6]]},"reference":[{"issue":"19","key":"148_CR1","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1001\/archinte.162.19.2229","volume":"162","author":"SI Blot","year":"2002","unstructured":"Blot SI, Vandewoude KH, Hoste EA, Colardyn FA. Outcome and attributable mortality in critically ill patients with bacteremia involving methicillin-susceptible and methicillin-resistant Staphylococcus aureus. Arch Internal Med. 2002;162(19):2229\u201335.","journal-title":"Arch Internal Med"},{"issue":"13","key":"148_CR2","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1001\/jama.2014.9743","volume":"312","author":"TL Holland","year":"2014","unstructured":"Holland TL, Arnold C, Fowler VG. Clinical management of Staphylococcus aureus bacteremia: a review. JAMA. 2014;312(13):1330\u201341.","journal-title":"JAMA"},{"key":"148_CR3","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1128\/AAC.00700-07","volume":"52","author":"SH Kim","year":"2008","unstructured":"Kim SH, Kim KH, Kim HB, et al. Outcome of vancomycin treatment in patients with methicillin-susceptible Staphylococcus aureus bacteremia. Antimicrob Agents Chemother. 2008;52:192\u20137.","journal-title":"Antimicrob Agents Chemother"},{"key":"148_CR4","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1186\/1471-2334-11-279","volume":"11","author":"ML Schweizer","year":"2011","unstructured":"Schweizer ML, Furuno JP, Harris AD, et al. Comparative effectiveness of nafcillin or cefazolin versus vancomycin in methicillin-susceptible Staphylococcus aureus bacteremia. BMC Infect Dis. 2011;11:279.","journal-title":"BMC Infect Dis"},{"key":"148_CR5","doi-asserted-by":"crossref","first-page":"5122","DOI":"10.1128\/AAC.00485-11","volume":"55","author":"S Lee","year":"2011","unstructured":"Lee S, Choe PG, Song K, et al. Is cefazolin inferior to nafcillin for the treatment of methicillin-susceptible Staphylococcus aureus bacteremia? Antimicrob Agents Chemother. 2011;55:5122\u20136.","journal-title":"Antimicrob Agents Chemother"},{"key":"148_CR6","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1111\/j.1469-0691.2010.03425.x","volume":"17","author":"M Paul","year":"2011","unstructured":"Paul M, Zemer-Wassercug N, Talker O, et al. Are all beta-lactams similarly effective in the treatment of methicillin-sensitive Staphylococcus aureus bacteremis? Clin Microbiol Infect. 2011;17:1581\u20136.","journal-title":"Clin Microbiol Infect"},{"key":"148_CR7","doi-asserted-by":"crossref","first-page":"4684","DOI":"10.1128\/AAC.00243-16","volume":"60","author":"S Pollet","year":"2016","unstructured":"Pollet S, Baxi SM, Rutherford GW, Doernberg SB, Bacchetti P, Chambersa HF. Cefazolin versus nafcillin for methicillin-sensitive Staphylococcus aureus bloodstream infection in a California tertiary medical center. Antimicrob Agents Chemother. 2016;60:4684\u20139.","journal-title":"Antimicrob Agents Chemother"},{"key":"148_CR8","doi-asserted-by":"crossref","first-page":"5232","DOI":"10.1128\/AAC.04677-14","volume":"59","author":"SN Rao","year":"2015","unstructured":"Rao SN, Rhodes NJ, Lee BJ, et al. Treatment outcomes with cefazolin versus oxacillin for deep-seated methicillin-susceptible Staphylococcus aureus bloodstream infections. Antimicrob Agents Chemother. 2015;59:5232\u20138.","journal-title":"Antimicrob Agents Chemother"},{"key":"148_CR9","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1093\/jac\/dku560","volume":"70","author":"A Bai","year":"2015","unstructured":"Bai A, Showler A, Burry L, et al. Comparative effectiveness of cefazolin versus cloxacillin as definitive antibiotic therapy for MSSA bacteremia: results from a multicenter cohort study. J Antimicrob Chemother. 2015;70:1539\u201349.","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"148_CR10","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1093\/cid\/ciu301","volume":"59","author":"I Youngster","year":"2014","unstructured":"Youngster I, Shenoy ES, Hooper DC, Nelson SB. Comparative evaluation of the tolerability of cefazolin and nafcillin for the treatment of methicillin-susceptible Staphyloccocus aureus infections in the outpatient setting. Clin Infect Dis. 2014;59(3):369\u201375.","journal-title":"Clin Infect Dis"},{"issue":"5","key":"148_CR11","doi-asserted-by":"crossref","first-page":"3090","DOI":"10.1128\/AAC.03122-15","volume":"60","author":"JA Viehman","year":"2016","unstructured":"Viehman JA, Oleksiuk LM, Sheridan KR, et al. Adverse events lead to drug discontinuation more commonly among patients who receive nafcillin than among those who receive oxacillin. Antimicrob Agents Chemother. 2016;60(5):3090\u2013309.","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"148_CR12","doi-asserted-by":"crossref","first-page":"R31","DOI":"10.1186\/cc5713","volume":"11","author":"RL Mehta","year":"2007","unstructured":"Mehta RL, Kellum JA, Shah SV, et al. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care. 2007;11(2):R31.","journal-title":"Crit Care"},{"issue":"2","key":"148_CR13","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1128\/AAC.02032-13","volume":"58","author":"F Valour","year":"2014","unstructured":"Valour F. Antimicrobial-related severe adverse events during treatment of bone and joint infection due to methicillin-susceptible Staphylococcus aureus. Antimicrob Agents Chemother. 2014;58(2):746\u201355.","journal-title":"Antimicrob Agents Chemother"},{"key":"148_CR14","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1161\/CIR.0000000000000296","volume":"132","author":"LM Baddour","year":"2015","unstructured":"Baddour LM, Wilson WR, Bayer AS, et al. Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications a scientific statement for healthcare professionals from the American Heart Association. Endorsed by the Infectious Diseases Society of America. Circulation. 2015;132:17\u20138.","journal-title":"Circulation"},{"issue":"8","key":"148_CR15","doi-asserted-by":"crossref","first-page":"3437","DOI":"10.1128\/AAC.00317-09","volume":"53","author":"EC Nannini","year":"2009","unstructured":"Nannini EC, Stryjewski ME, Singh KV, et al. Inoculum effect with cefazolin among clinical isolates of methicillin-susceptible Staphyloccocus aureus: frequency and possible cause of cefazolin treatment failure. Antimicrob Agents Chemother. 2009;53(8):3437\u201341.","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-017-0148-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,5,26]],"date-time":"2017-05-26T10:32:03Z","timestamp":1495794723000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40121-017-0148-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,6]]},"references-count":15,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["148"],"URL":"https:\/\/doi.org\/10.1007\/s40121-017-0148-z","relation":{},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"value":"2193-8229","type":"print"},{"value":"2193-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,6]]}}}